No Data
Earnings Preview: Novartis AG to Report Financial Results Pre-market on April 29
Novartis, Sanofi CEOs Push for EU Drug Pricing Reforms Amid Tariff Concerns
AstraZeneca CEO Urges Europe to Spend More on Health or Risk Falling Behind -- Market Talk
European pharmaceutical giants are calling for an increase in pharmaceutical prices to the same level as in the USA.
The CEOs of the two major pharmaceutical giants in Europe, Novartis and Sanofi, stated in an open letter on Wednesday that in order to attract investment, the EU should allow pharmaceutical prices to rise to the levels found in the USA. Pharmaceutical prices in the USA are the highest in the world, often nearly three times that of other developed countries. Novartis CEO Vas Narasimhan and Sanofi CEO Paul Hudson wrote, "Price controls and austerity measures in Europe have reduced the attractiveness of its market." They added, "In the context of declining biopharmaceutical competitiveness in Europe, uncertainty about tariffs further diminishes the motivation to invest in the EU." They believe that EU
Roche Plans $50 Billion US Investment Over 5 Years With 12,000 New Jobs
Trump Mulls Cutting US Drug Prices to International Levels, Reuters Reports
Expand
HH1000 : aren't they doing an offering. diluting shares. it's gonna make the price drop. no thanks for buying
Tonyco HH1000 :
DazzlerAus HH1000 : they are not necessarily doing an offering S3 expire it oretty standard for these conpanies to have a standing S3 in case its needed often it just insurance against an unexpected result ie if suddenly their main drug started resulting in bad side effects